{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:04:11Z","timestamp":1770822251510,"version":"3.50.1"},"reference-count":208,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.4065\/80.9.1220","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:26:10Z","timestamp":1232760370000},"page":"1220-1232","source":"Crossref","is-referenced-by-count":34,"title":["bcr\/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment"],"prefix":"10.4065","volume":"80","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/80.9.1220_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/80.9.1220_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM197308092890608","article-title":"Clonal origin of chronic myelocytic leukemia","volume":"289","author":"Barr","year":"1973","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1172\/JCI109193","article-title":"Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells","volume":"62","author":"Fialkow","year":"1978","journal-title":"J Clin Invest"},{"key":"10.4065\/80.9.1220_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/287049a0","article-title":"Involvement of the B-lymphoid system in chronic myelogenous leukaemia","volume":"287","author":"Martin","year":"1980","journal-title":"Nature"},{"key":"10.4065\/80.9.1220_bib9","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib10","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.4065\/80.9.1220_bib11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/80.9.1220_bib12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.4065\/80.9.1220_bib13","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.4065\/80.9.1220_bib15","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.4065\/80.9.1220_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and the myelodysplastic syndrome","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib17","author":"Jones"},{"key":"10.4065\/80.9.1220_bib18","unstructured":"Tefferi A, Gilliland DG. Classification of myeloproliferative disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol. In press."},{"key":"10.4065\/80.9.1220_bib19","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra035363","article-title":"Thrombocytosis","volume":"350","author":"Schafer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1054\/blre.2001.0158","article-title":"Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management","volume":"15","author":"Tefferi","year":"2001","journal-title":"Blood Rev"},{"key":"10.4065\/80.9.1220_bib21","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.4065\/80.9.1220_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/000992289403300605","article-title":"Thrombocytosis: etiologic analysis of 663 patients","volume":"33","author":"Yohannan","year":"1994","journal-title":"Clin Pediatr (Phila)"},{"key":"10.4065\/80.9.1220_bib23","first-page":"309","article-title":"Thrombocytosis in children at one medical center of southern Taiwan","volume":"40","author":"Chen","year":"1999","journal-title":"Acta Paediatr Taiwan"},{"key":"10.4065\/80.9.1220_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.1991.tb00383.x","article-title":"Thrombocytosis in adults: analysis of 777 patients","volume":"229","author":"Santhosh-Kumar","year":"1991","journal-title":"J Intern Med"},{"key":"10.4065\/80.9.1220_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000206719","article-title":"Thrombocytosis and microthrombocytosis: a clinical evaluation of 372 cases","volume":"70","author":"Robbins","year":"1983","journal-title":"Acta Haematol"},{"key":"10.4065\/80.9.1220_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0002-9343(94)90150-3","article-title":"Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases","volume":"96","author":"Buss","year":"1994","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.4065\/80.9.1220_bib27","first-page":"S95","article-title":"Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis","volume":"83","author":"Chuncharunee","year":"2000","journal-title":"J Med Assoc Thai"},{"key":"10.4065\/80.9.1220_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-9343(94)90306-9","article-title":"Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis","volume":"97","author":"Tefferi","year":"1994","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib29","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib30","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2003-10-3502","article-title":"Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia [letter]","volume":"103","author":"Florensa","year":"2004","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/bja\/aeh286","article-title":"Thrombocytosis after trauma: incidence, aetiology, and clinical significance","volume":"94","author":"Valade","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.4065\/80.9.1220_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.2830270202","article-title":"Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome","volume":"27","author":"Stoll","year":"1988","journal-title":"Am J Hematol"},{"key":"10.4065\/80.9.1220_bib33","first-page":"1126","article-title":"Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2000","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.9.1220_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000064754","article-title":"Cytogenetic and molecular genetic aspects of essential thrombocythemia","volume":"108","author":"Steensma","year":"2002","journal-title":"Acta Haematol"},{"key":"10.4065\/80.9.1220_bib36","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib38","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y","article-title":"Essential thrombocythemias: clinical evolutionary and biological data","volume":"58","author":"Bellucci","year":"1986","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2141.1993.tb08272.x","article-title":"Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors","volume":"83","author":"Watson","year":"1993","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s002770050555","article-title":"Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia","volume":"78","author":"Bazzan","year":"1999","journal-title":"Ann Hematol"},{"key":"10.4065\/80.9.1220_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.4065\/80.9.1220_bib42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.9.1220_bib43","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib44","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1046\/j.1537-2995.2002.00210.x","article-title":"Erythromelalgia due to essential thrombocythemia","volume":"42","author":"McCarthy","year":"2002","journal-title":"Transfusion"},{"key":"10.4065\/80.9.1220_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood.V64.5.981.981","article-title":"Acquired von Willebrand's disease in the myeloproliferative syndrome","volume":"64","author":"Budde","year":"1984","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","article-title":"Clinical course of essential thrombocythemia in 147 cases","volume":"66","author":"Fenaux","year":"1990","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib48","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk thrombocythaemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9343(00)00449-6","article-title":"A clinical update in polycythemia vera and essential thrombocythemia","volume":"109","author":"Tefferi","year":"2000","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archderm.1975.01630140041002","article-title":"Skin changes secondary to hydroxyurea therapy","volume":"111","author":"Kennedy","year":"1975","journal-title":"Arch Dermatol"},{"issue":"3, suppl 9","key":"10.4065\/80.9.1220_bib52","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin Oncol"},{"key":"10.4065\/80.9.1220_bib53","first-page":"217","article-title":"Hydroxyurea and lower leg ulcers","volume":"52","author":"Nguyen","year":"1993","journal-title":"Cutis"},{"key":"10.4065\/80.9.1220_bib54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/106002809502900205","article-title":"Hydroxyurea-induced fever: case report and review of the literature","volume":"29","author":"Lossos","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.4065\/80.9.1220_bib55","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"2, pt 1","key":"10.4065\/80.9.1220_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0190-9622(97)70276-7","article-title":"Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea","volume":"36","author":"Daoud","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.4065\/80.9.1220_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","article-title":"Hydroxyurea-induced leg ulceration in 14 patients","volume":"128","author":"Best","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.4065\/80.9.1220_bib58","first-page":"172","article-title":"Hydroxyurea: an overview","volume":"13","author":"Stevens","year":"1999","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.4065\/80.9.1220_bib59","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.V96.4.1582","article-title":"Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib60","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states: experience in 577 patients","volume":"92","author":"Anagrelide Study Group","year":"1992","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib62","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V79.8.1931.1931","article-title":"Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans","volume":"79","author":"Mazur","year":"1992","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib63","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-199447050-00007","article-title":"Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia","volume":"47","author":"Spencer","year":"1994","journal-title":"Drugs"},{"key":"10.4065\/80.9.1220_bib64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2141.1997.3503164.x","article-title":"The effects of anagrelide on human megakaryocytopoiesis","volume":"99","author":"Solberg","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2007-996112","article-title":"Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications","volume":"23","author":"Tefferi","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.4065\/80.9.1220_bib66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib67","first-page":"1394","article-title":"Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia [letter]","volume":"89","author":"Jurgens","year":"2004","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: a review","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.9.1220_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2141.1989.tb04251.x","article-title":"In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia","volume":"71","author":"Gugliotta","year":"1989","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.4065\/80.9.1220_bib71","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1055\/s-2007-996123","article-title":"Interferon-alpha therapy in polycythemia vera and essential thrombocythemia","volume":"23","author":"Elliott","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.4065\/80.9.1220_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0009-9260(67)80076-X","article-title":"Radioactive phosphorus in the treatment of polycythaemia: a review of ten years' experience","volume":"18","author":"Arthur","year":"1967","journal-title":"Clin Radiol"},{"key":"10.4065\/80.9.1220_bib74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0268-960X(97)90009-6","article-title":"Use of radioactive phosphorus in haematology","volume":"11","author":"Roberts","year":"1997","journal-title":"Blood Rev"},{"key":"10.4065\/80.9.1220_bib75","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0009-9260(89)80092-3","article-title":"The treatment of essential thrombocythaemia with radioactive phosphorus","volume":"40","author":"Wagner","year":"1989","journal-title":"Clin Radiol"},{"key":"10.4065\/80.9.1220_bib76","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V59.5.890.890","article-title":"Pipobroman therapy of polycythemia vera","volume":"59","author":"Najman","year":"1982","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.1967.03120200097020","article-title":"Evaluation of two antineoplastic agents, pipobroman (vercyte) and thioguanine","volume":"200","year":"1967","journal-title":"JAMA"},{"key":"10.4065\/80.9.1220_bib78","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients","volume":"85","author":"Passamonti","year":"2000","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib79","first-page":"306","article-title":"Pipobroman therapy of essential thrombocythemia","volume":"37","author":"Mazzucconi","year":"1986","journal-title":"Scand J Haematol"},{"key":"10.4065\/80.9.1220_bib80","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib81","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1995.00430110137015","article-title":"Outcome analysis of 34 pregnancies in women with essential thrombocythemia","volume":"155","author":"Beressi","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.4065\/80.9.1220_bib82","first-page":"6","article-title":"The medical research council PT1 trial in essential thrombocythemia [abstract]","volume":"104","author":"Green","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/80.9.1220_bib83","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib84","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis [letter]","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib85","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1365-2141.2002.3346_1.x","article-title":"Second malignancies in patients with essential thrombocythaemia [letter]","volume":"116","author":"Randi","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib86","first-page":"1523","article-title":"Bone marrow biopsy and aspirate evaluation in 90 patients with essential thrombocythemia treated with PEG interferon alpha-2b: preliminary results [abstract]","volume":"104","author":"Gugliotta","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.4065\/80.9.1220_bib87","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1046\/j.1365-4362.2002.01623.x","article-title":"Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia","volume":"41","author":"Demircay","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.4065\/80.9.1220_bib88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00280-002-0533-4","article-title":"Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.4065\/80.9.1220_bib89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W","article-title":"Thrombotic complications in essential thrombocythemia with relatively low platelet counts","volume":"56","author":"Regev","year":"1997","journal-title":"Am J Hematol"},{"key":"10.4065\/80.9.1220_bib90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy, 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [published correction appears in BMJ. 1994;308:1540]","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.4065\/80.9.1220_bib91","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0950-3536(87)80020-3","article-title":"The contracted plasma volume syndromes (relative polycythaemias) and their haemorheological significance","volume":"1","author":"Isbister","year":"1987","journal-title":"Baillieres Clin Haematol"},{"key":"10.4065\/80.9.1220_bib92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1034\/j.1600-0609.2000.065005285.x","article-title":"Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to \u2018apparent polycythemia.\u2019","volume":"65","author":"Fairbanks","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.4065\/80.9.1220_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4065\/78.2.174","article-title":"Polycythemia vera: a comprehensive review and clinical recommendations","volume":"78","author":"Tefferi","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.9.1220_bib94","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat Genet"},{"key":"10.4065\/80.9.1220_bib95","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V56.2.246.246","article-title":"Hemoglobin Ohio (beta 142 Ala replaced by): a new abnormal hemoglobin with high oxygen affinity and erythrocytosis","volume":"56","author":"Moo-Penn","year":"1980","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib96","first-page":"69","article-title":"Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis [in French]","volume":"26","author":"Galacteros","year":"1984","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.4065\/80.9.1220_bib97","first-page":"109","article-title":"Congenital polycythemias\/erythrocytoses","volume":"90","author":"Gordeuk","year":"2005","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00277-004-0985-1","article-title":"Childhood polycythemias\/erythrocytoses: classification, diagnosis, clinical presentation, and treatment","volume":"84","author":"Cario","year":"2005","journal-title":"Ann Hematol"},{"key":"10.4065\/80.9.1220_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.V86.1.15.bloodjournal86115","article-title":"Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin","volume":"86","author":"Sokol","year":"1995","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/thx.32.3.317","article-title":"Secondary polycythaemia in chronic respiratory insufficiency","volume":"32","author":"Vanuxem","year":"1977","journal-title":"Thorax"},{"key":"10.4065\/80.9.1220_bib101","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0022-3476(87)80544-9","article-title":"Serum erythropoietin levels in patients with congenital heart disease","volume":"110","author":"Tyndall","year":"1987","journal-title":"J Pediatr"},{"key":"10.4065\/80.9.1220_bib102","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1152\/jappl.1985.59.2.360","article-title":"Serum erythropoietin in humans at high altitude and its relation to plasma renin","volume":"59","author":"Milledge","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.4065\/80.9.1220_bib103","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM198809293191319","article-title":"Carbon monoxide poisoning presenting as polycythemia [letter]","volume":"319","author":"DiMarco","year":"1988","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib104","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJM197801052980102","article-title":"Smokers' polycythemia","volume":"298","author":"Smith","year":"1978","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.106.3.787","article-title":"Hematocrit levels in sleep apnea","volume":"106","author":"Hoffstein","year":"1994","journal-title":"Chest"},{"key":"10.4065\/80.9.1220_bib106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.1.5531.18","article-title":"Renal artery stenosis with hypertension and high haematocrit","volume":"1","author":"Hudgson","year":"1967","journal-title":"Br Med J"},{"key":"10.4065\/80.9.1220_bib107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1096-9098(200011)75:3<197::AID-JSO8>3.0.CO;2-I","article-title":"Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma","volume":"75","author":"Matsuyama","year":"2000","journal-title":"J Surg Oncol"},{"key":"10.4065\/80.9.1220_bib108","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/00042737-199912000-00010","article-title":"The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients","volume":"11","author":"Ndububa","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.4065\/80.9.1220_bib109","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/blood.V99.10.3562","article-title":"Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma","volume":"99","author":"Wiesener","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3171\/jns.1970.32.6.0700","article-title":"Hemangioblastoma of the cerebellum associated with erythrocytosis and an unusual blood supply: case report","volume":"32","author":"Skultety","year":"1970","journal-title":"J Neurosurg"},{"key":"10.4065\/80.9.1220_bib111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/8756-3282(91)90069-U","article-title":"Parathyroid carcinoma associated with polycythemia vera","volume":"12","author":"Weinstein","year":"1991","journal-title":"Bone"},{"key":"10.4065\/80.9.1220_bib112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2141.2001.02682.x","article-title":"Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis","volume":"113","author":"Suzuki","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib113","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/archinte.1983.00350090204042","article-title":"Polycystic kidney disease and polycythemia vera: occurrence in a patient receiving hemodialysis","volume":"143","author":"Jermanovich","year":"1983","journal-title":"Arch Intern Med"},{"key":"10.4065\/80.9.1220_bib114","first-page":"197","article-title":"Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion","volume":"37","author":"Drenou","year":"1995","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.4065\/80.9.1220_bib115","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood.V81.6.1593.1593","article-title":"Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis","volume":"81","author":"Bruneval","year":"1993","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib116","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-4757-3401-0_14","article-title":"Erythropoietin use and abuse: when physiology and pharmacology collide","volume":"502","author":"Spivak","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"10.4065\/80.9.1220_bib117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<263::AID-AJH19>3.0.CO;2-U","article-title":"Androgen-induced erythrocytosis [letter]","volume":"59","author":"Dickerman","year":"1998","journal-title":"Am J Hematol"},{"key":"10.4065\/80.9.1220_bib118","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ki.1983.86","article-title":"Postrenal transplant erythrocytosis: a review of 53 patients","volume":"23","author":"Wickre","year":"1983","journal-title":"Kidney Int"},{"key":"10.4065\/80.9.1220_bib119","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00007890-199907150-00012","article-title":"Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis","volume":"68","author":"Glicklich","year":"1999","journal-title":"Transplantation"},{"key":"10.4065\/80.9.1220_bib120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2003.11.006","article-title":"Angiotensin II receptor type 1 expression in erythroid progenitors: implications for the pathogenesis of postrenal transplant erythrocytosis","volume":"24","author":"Mrug","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.4065\/80.9.1220_bib121","first-page":"363","article-title":"Die Bedeutung der Blutdruckmessung fur die Praxis","volume":"83","author":"Geisbock","year":"1905","journal-title":"Arch Clin Med (Leipzig)"},{"key":"10.4065\/80.9.1220_bib122","first-page":"498","article-title":"Relative polycythemia: the polycythemia of stress","volume":"24","author":"Lawrence","year":"1952","journal-title":"Yale J Biol Med"},{"key":"10.4065\/80.9.1220_bib123","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/10245332.1999.11746463","article-title":"Myeloproliferative disease: polycythemia vera: the packed cell volume and the curious logic of the red cell mass","volume":"4","author":"Fairbanks","year":"2000","journal-title":"Hematology"},{"key":"10.4065\/80.9.1220_bib124","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(71)90149-5","article-title":"Spurious (relative) polycythemia: a nonexistent disease","volume":"50","author":"Brown","year":"1971","journal-title":"Am J Med"},{"key":"10.4065\/80.9.1220_bib125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/archinte.1960.03860180108020","article-title":"Odd men out: individuals with extreme values","volume":"115","author":"Fessel","year":"1965","journal-title":"Arch Intern Med"},{"key":"10.4065\/80.9.1220_bib126","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/bcmd.1996.0024","article-title":"Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods","volume":"22","author":"Fairbanks","year":"1996","journal-title":"Blood Cells Mol Dis"},{"key":"10.4065\/80.9.1220_bib127","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.1971.tb02698.x","article-title":"The management of polycythaemia vera","volume":"21","author":"Wasserman","year":"1971","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib128","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","article-title":"Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia","volume":"117","author":"Messinezy","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJM198607313150503","article-title":"Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis","volume":"315","author":"Cotes","year":"1986","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib131","first-page":"368","article-title":"The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias","volume":"86","author":"Thiele","year":"2001","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib132","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-4608(87)90183-X","article-title":"A chromosomal profile of polycythemia vera","volume":"25","author":"Rege-Cambrin","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/80.9.1220_bib133","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V72.2.386.386","article-title":"A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course","volume":"72","author":"Swolin","year":"1988","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib134","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0025-6196(12)61011-8","article-title":"Chromosome studies in 104 patients with polycythemia vera","volume":"66","author":"Diez-Martin","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.9.1220_bib135","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.V96.2.771","article-title":"Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib136","first-page":"64","article-title":"In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders","volume":"34","author":"Weinberg","year":"1997","journal-title":"Semin Hematol"},{"key":"10.4065\/80.9.1220_bib137","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera","volume":"95","author":"Temerinac","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2004.05149.x","article-title":"Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay","volume":"127","author":"Koch","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib139","series-title":"Polycythemia Vera and the Myeloproliferative Disorders","first-page":"166","article-title":"Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group","author":"Berk","year":"1995"},{"key":"10.4065\/80.9.1220_bib140","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.4065\/80.9.1220_bib141","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"issue":"suppl 2","key":"10.4065\/80.9.1220_bib142","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF03165137","article-title":"Treatment of polycythemia vera with recombinant interferon","volume":"76","author":"Silver","year":"2002","journal-title":"Int J Hematol"},{"key":"10.4065\/80.9.1220_bib143","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.V99.7.2627","article-title":"Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus [letter]","volume":"99","author":"Tefferi","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib144","first-page":"13","article-title":"Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib146","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib147","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/hupa.2003.58","article-title":"Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia","volume":"34","author":"Buesche","year":"2003","journal-title":"Hum Pathol"},{"key":"10.4065\/80.9.1220_bib148","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0145-2126(01)00055-8","article-title":"Myelodysplasia with fibrosis: a distinct entity?","volume":"25","author":"Steensma","year":"2001","journal-title":"Leuk Res"},{"key":"10.4065\/80.9.1220_bib149","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.9.1220_bib150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/mpo.2950190111","article-title":"Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: response to corticotherapy","volume":"19","author":"Michel","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"10.4065\/80.9.1220_bib151","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/152581602753448603","article-title":"Bone marrow angiogenesis in systemic mast cell disease","volume":"11","author":"Baek","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.4065\/80.9.1220_bib152","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1986.tb02900.x","article-title":"Acute megakaryoblastic leukaemia: a prospective study of its identification and treatment","volume":"62","author":"Ruiz-Arguelles","year":"1986","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib153","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000041054","article-title":"Acute promyelocytic leukemia with marrow fibrosis at initial presentation: possible involvement of transforming growth factor-beta(1)","volume":"103","author":"Mori","year":"2000","journal-title":"Acta Haematol"},{"key":"10.4065\/80.9.1220_bib154","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/jcp.42.12.1253","article-title":"Bone marrow fibrosis in childhood acute lymphoblastic leukaemia","volume":"42","author":"Wallis","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.4065\/80.9.1220_bib155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1984.tb02217.x","article-title":"Malignant (acute) myelosclerosis\u2014a clinical and pathological study in 6 patients","volume":"33","author":"Thiele","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.4065\/80.9.1220_bib156","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.2830340411","article-title":"Idiopathic myelofibrosis: a clinical study of 80 patients","volume":"34","author":"Hasselbalch","year":"1990","journal-title":"Am J Hematol"},{"key":"10.4065\/80.9.1220_bib157","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI19540","article-title":"TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia","volume":"113","author":"Shehata","year":"2004","journal-title":"J Clin Invest"},{"key":"10.4065\/80.9.1220_bib158","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/1097-0142(19891015)64:8<1720::AID-CNCR2820640828>3.0.CO;2-L","article-title":"Hodgkin's disease presenting as myelofibrosis","volume":"64","author":"Meadows","year":"1989","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib159","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00277-003-0806-y","article-title":"Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta","volume":"83","author":"Matsunaga","year":"2004","journal-title":"Ann Hematol"},{"key":"10.4065\/80.9.1220_bib160","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/1097-0142(19940201)73:3<625::AID-CNCR2820730320>3.0.CO;2-A","article-title":"Plasma cell dyscrasia with marrow fibrosis: a reversible syndrome mimicking agnogenic myeloid metaplasia","volume":"73","author":"Meerkin","year":"1994","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib161","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/1097-0142(196911)24:5<1041::AID-CNCR2820240526>3.0.CO;2-C","article-title":"Metastatic carcinoma simulating agnogenic myeloid metaplasia and myelofibrosis","volume":"24","author":"Kiely","year":"1969","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib162","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-199405000-00003","article-title":"Autoimmune myelofibrosis: a steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus","volume":"73","author":"Paquette","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"10.4065\/80.9.1220_bib163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000204592","article-title":"Myelofibrosis and systemic lupus erythematosus: reversal of fibrosis with high-dose corticosteroid therapy","volume":"88","author":"Inoue","year":"1992","journal-title":"Acta Haematol"},{"key":"10.4065\/80.9.1220_bib164","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/S0037-86822000000400005","article-title":"Bone marrow fibrosis (pseudo-myelofibrosis) in human kala-azar","volume":"33","author":"Rocha Filho","year":"2000","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.4065\/80.9.1220_bib165","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/340524","article-title":"Reversible myelofibrosis induced by tuberculosis","volume":"34","author":"Viallard","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.4065\/80.9.1220_bib166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2003.04570.x","article-title":"Abnormal osteoclasts and bone marrow fibrosis in Paget's disease of the bone","volume":"124","author":"Murrin","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib167","first-page":"180","article-title":"Haematological changes in HIV infection","volume":"46","author":"Sitalakshmi","year":"2003","journal-title":"Indian J Pathol Microbiol"},{"key":"10.4065\/80.9.1220_bib168","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s004310051215","article-title":"Myelofibrosis: an unusual presentation of vitamin D-deficient rickets","volume":"158","author":"Stephan","year":"1999","journal-title":"Eur J Pediatr"},{"key":"10.4065\/80.9.1220_bib169","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1159\/000188961","article-title":"Myelofibrosis secondary to renal osteodystrophy","volume":"72","author":"Nomura","year":"1996","journal-title":"Nephron"},{"key":"10.4065\/80.9.1220_bib170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-2004-817820","article-title":"Myelofibrosis secondary to hyperparathyroidism","volume":"112","author":"Kumbasar","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.4065\/80.9.1220_bib171","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/mgme.2001.3247","article-title":"A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics","volume":"74","author":"Falik-Zaccai","year":"2001","journal-title":"Mol Genet Metab"},{"key":"10.4065\/80.9.1220_bib172","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00043426-200403000-00005","article-title":"Fatal familial infantile myelofibrosis","volume":"26","author":"Sheikha","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.4065\/80.9.1220_bib173","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib174","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib175","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","article-title":"Identification of \u2018short-lived\u2019 and \u2018long-lived\u2019 patients at presentation of idiopathic myelofibrosis","volume":"97","author":"Cervantes","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib176","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib177","series-title":"Agnogenic Myeloid Metaplasia","author":"Silverstein","year":"1975"},{"key":"10.4065\/80.9.1220_bib178","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1056\/NEJM196602242740802","article-title":"Androgens and erythropoiesis, 3: further evaluation of testosterone treatment of myelofibrosis","volume":"274","author":"Gardner","year":"1966","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib179","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4","article-title":"Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival","volume":"49","author":"Besa","year":"1982","journal-title":"Cancer"},{"key":"10.4065\/80.9.1220_bib180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.10076","article-title":"Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin","volume":"70","author":"Hasselbalch","year":"2002","journal-title":"Am J Hematol"},{"key":"10.4065\/80.9.1220_bib181","first-page":"616","article-title":"rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: experience in 6 patients and meta-analytical approach","volume":"83","author":"Rodriguez","year":"1998","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib182","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2141.1994.tb04853.x","article-title":"Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia [letter]","volume":"86","author":"Tefferi","year":"1994","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib183","first-page":"371","article-title":"Erythropoietin treatment of idiopathic myelofibrosis","volume":"78","author":"Aloe Spiriti","year":"1993","journal-title":"Haematologica"},{"key":"10.4065\/80.9.1220_bib184","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","article-title":"Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea","volume":"41","author":"Lofvenberg","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.4065\/80.9.1220_bib185","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.leu.2402596","article-title":"Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study","volume":"16","author":"Piccaluga","year":"2002","journal-title":"Leukemia"},{"key":"10.4065\/80.9.1220_bib186","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","article-title":"Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"19","author":"Merup","year":"2002","journal-title":"Med Oncol"},{"key":"10.4065\/80.9.1220_bib187","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib188","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.03072.x","article-title":"Thalidomide in agnogenic and secondary myelofibrosis","volume":"115","author":"Canepa","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib189","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","article-title":"Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"114","author":"Barosi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib190","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.9.1220_bib191","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib192","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib193","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2141.2002.03695.x","article-title":"Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia","volume":"118","author":"Steensma","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib194","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4065\/78.10.1223","article-title":"Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment","volume":"78","author":"Koch","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/80.9.1220_bib195","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","article-title":"Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia","volume":"103","author":"Elliott","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib196","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2001.00342.x","article-title":"Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia","volume":"66","author":"Tefferi","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.4065\/80.9.1220_bib197","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","article-title":"Unexplained pulmonary hypertension in chronic myeloproliferative disorders","volume":"120","author":"Dingli","year":"2001","journal-title":"Chest"},{"key":"10.4065\/80.9.1220_bib198","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib199","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bmt.1704075","article-title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers","volume":"32","author":"Daly","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/80.9.1220_bib201","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/80.9.1220_bib202","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib203","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2141.2002.03884.x","article-title":"Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia","volume":"119","author":"Hessling","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib204","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib205","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.4065\/80.9.1220_bib206","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM200008313430913","article-title":"Myelofibrosis with myeloid metaplasia [letter]","volume":"343","author":"Guardiola","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/80.9.1220_bib207","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","article-title":"Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups","volume":"102","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/80.9.1220_bib208","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611619708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611619708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:20:51Z","timestamp":1589505651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611619708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":208,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0025619611619708"],"URL":"https:\/\/doi.org\/10.4065\/80.9.1220","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}